Production and regulatory issues for theranostics

Francesco Giammarile; Diana Paez; Richard Zimmermann; Cathy S. Cutler; Amirreza Jalilian; Aruna Korde; Peter Knoll; Nayyereh Ayati; Jason S. Lewis; Suzanne E. Lapi; Roberto C. Delgado Bolton; Jolanta Kunikowska; Enrique Estrada Lobato; Jean-Luc Urbain; Ola Holmberg; May Abdel-Wahab; Andrew M. Scott

doi:10.1016/S1470-2045(24)00041-X

Production and regulatory issues for theranostics

Francesco Giammarile, Diana Paez, Richard Zimmermann, Cathy S. Cutler, Amirreza Jalilian, Aruna Korde, Peter Knoll, Nayyereh Ayati, Jason S. Lewis, Suzanne E. Lapi, Roberto C. Delgado Bolton, Jolanta Kunikowska, Enrique Estrada Lobato, Jean-Luc Urbain, Ola Holmberg, May Abdel-Wahab, Andrew M. Scott

Centre for Health Economics

Research output: Contribution to journal › Review Article › Other › peer-review

3 Citations (Scopus)

Abstract

Theranostics has become a major area of innovation and progress in cancer care over the last decade. In view of the introduction of approved therapeutics in neuroendocrine tumours and prostate cancer in the last 10 years, the ability to provide access to these treatments has emerged as a key factor in ensuring global benefits from this cancer therapy approach. In this Series paper we explore the issues that affect access to and availability of theranostic radiopharmaceuticals, including supply and regulatory issues that might affect the availability of theranostic treatments for patients with cancer.

Original language	English
Pages (from-to)	e260-e269
Number of pages	10
Journal	The Lancet Oncology
Volume	25
Issue number	6
DOIs	https://doi.org/10.1016/S1470-2045(24)00041-X
Publication status	Published - Jun 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(24)00041-X

Cite this

Giammarile, F., Paez, D., Zimmermann, R., Cutler, C. S., Jalilian, A., Korde, A., Knoll, P., Ayati, N., Lewis, J. S., Lapi, S. E., Delgado Bolton, R. C., Kunikowska, J., Estrada Lobato, E., Urbain, J.-L., Holmberg, O., Abdel-Wahab, M., & Scott, A. M. (2024). Production and regulatory issues for theranostics. The Lancet Oncology, 25(6), e260-e269. https://doi.org/10.1016/S1470-2045(24)00041-X

@article{98fcabd2995e47e1bbd4631bdfddae8e,

title = "Production and regulatory issues for theranostics",

abstract = "Theranostics has become a major area of innovation and progress in cancer care over the last decade. In view of the introduction of approved therapeutics in neuroendocrine tumours and prostate cancer in the last 10 years, the ability to provide access to these treatments has emerged as a key factor in ensuring global benefits from this cancer therapy approach. In this Series paper we explore the issues that affect access to and availability of theranostic radiopharmaceuticals, including supply and regulatory issues that might affect the availability of theranostic treatments for patients with cancer.",

author = "Francesco Giammarile and Diana Paez and Richard Zimmermann and Cutler, {Cathy S.} and Amirreza Jalilian and Aruna Korde and Peter Knoll and Nayyereh Ayati and Lewis, {Jason S.} and Lapi, {Suzanne E.} and {Delgado Bolton}, {Roberto C.} and Jolanta Kunikowska and {Estrada Lobato}, Enrique and Jean-Luc Urbain and Ola Holmberg and May Abdel-Wahab and Scott, {Andrew M.}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = jun,

doi = "10.1016/S1470-2045(24)00041-X",

language = "English",

volume = "25",

pages = "e260--e269",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier",

number = "6",

}

Giammarile, F, Paez, D, Zimmermann, R, Cutler, CS, Jalilian, A, Korde, A, Knoll, P, Ayati, N, Lewis, JS, Lapi, SE, Delgado Bolton, RC, Kunikowska, J, Estrada Lobato, E, Urbain, J-L, Holmberg, O, Abdel-Wahab, M & Scott, AM 2024, 'Production and regulatory issues for theranostics', The Lancet Oncology, vol. 25, no. 6, pp. e260-e269. https://doi.org/10.1016/S1470-2045(24)00041-X

TY - JOUR

T1 - Production and regulatory issues for theranostics

AU - Giammarile, Francesco

AU - Paez, Diana

AU - Zimmermann, Richard

AU - Cutler, Cathy S.

AU - Jalilian, Amirreza

AU - Korde, Aruna

AU - Knoll, Peter

AU - Ayati, Nayyereh

AU - Lewis, Jason S.

AU - Lapi, Suzanne E.

AU - Delgado Bolton, Roberto C.

AU - Kunikowska, Jolanta

AU - Estrada Lobato, Enrique

AU - Urbain, Jean-Luc

AU - Holmberg, Ola

AU - Abdel-Wahab, May

AU - Scott, Andrew M.

PY - 2024/6

Y1 - 2024/6

N2 - Theranostics has become a major area of innovation and progress in cancer care over the last decade. In view of the introduction of approved therapeutics in neuroendocrine tumours and prostate cancer in the last 10 years, the ability to provide access to these treatments has emerged as a key factor in ensuring global benefits from this cancer therapy approach. In this Series paper we explore the issues that affect access to and availability of theranostic radiopharmaceuticals, including supply and regulatory issues that might affect the availability of theranostic treatments for patients with cancer.

AB - Theranostics has become a major area of innovation and progress in cancer care over the last decade. In view of the introduction of approved therapeutics in neuroendocrine tumours and prostate cancer in the last 10 years, the ability to provide access to these treatments has emerged as a key factor in ensuring global benefits from this cancer therapy approach. In this Series paper we explore the issues that affect access to and availability of theranostic radiopharmaceuticals, including supply and regulatory issues that might affect the availability of theranostic treatments for patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=85194056514&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(24)00041-X

DO - 10.1016/S1470-2045(24)00041-X

M3 - Review Article

C2 - 38821100

AN - SCOPUS:85194056514

SN - 1470-2045

VL - 25

SP - e260-e269

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 6

ER -

Production and regulatory issues for theranostics

Abstract

UN SDGs

Access to Document

Other files and links

Radiotherapy and theranostics: a Lancet Oncology Commission

Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics

Cite this